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Regulation of photoreceptor phosphodiesterase (PDE6) activity is responsible for the speed, sensitivity, and 
recovery of the photoresponse during visual signaling in vertebrate photoreceptor cells. It is hypothesized 
that the physiological differences in the light responsiveness of rods and cones may result in part from 
differences in the structure and regulation of the distinct isoforms of rod and cone PDE6. Although rod and 
cone PDE6 catalytic subunits share a similar domain organization consisting of tandem GAF domains 
(GAFa and GAFb) and a catalytic domain, cone PDE6 is a homodimer whereas the rod PDE6 catalytic 
dimer is composed of two homologous catalytic subunits. Here we provide the x-ray crystal structure of 
cone GAFab regulatory domain solved at 3.3 Å resolution in conjunction with chemical cross-linking and 
mass spectrometric analysis of conformational changes to GAFab induced upon binding of cGMP and the 
PDE6 inhibitory γ-subunit (Pγ). Ligand-induced changes in cross-linked residues implicate the α4-helix of 
GAFa (close to the cGMP binding site) and the β1/β2 loop of GAFb as key motifs that have been  previously 
proposed to communicate with the catalytic domains of PDE6. Molecular dynamics (MD) simulations of 
cone GAFab revealed asymmetry in the two GAFab subunits forming the homodimer and allosteric 
perturbations on cGMP binding. Cross-linking of Pγ to GAFab in conjunction with solution NMR 
spectroscopy of isotopically labeled Pγ identified the central polycationic region of Pγ interacting with the 
GAFb domain. These results provide a mechanistic basis for developing allosteric activators of PDE6 with 
therapeutic implications for halting the progression of certain retinal degenerative diseases. 
 
Introduction 
The vertebrate retina contains two types of photoreceptors, rods and cones, that differ in their 
responsiveness to light. For example, while rods are hundred times more light-sensitive than cones, cone 
electrical responses are faster during both the excitation and recovery phases {Korenbrot, 2012 
#7097;Ingram, 2016 #7800}. The first step in vision involves photoisomerization of the visual pigment 
rhodopsin which activates a G-protein mediated signaling cascade leading to activation of a cGMP-
specific phosphodiesterase (PDE6) in the outer segment of rod and cone cells. This results in lowering of 
cGMP levels and closure of cGMP-gated ion channel leading to membrane hyperpolarization 
{Arshavsky, 2012 #7055}. Rod and cone photoreceptors express homologues of all of the 
phototransduction components mentioned above {Korenbrot, 2012 #7097}. Whereas cone PDE6 (gene 
name: PDE6C) consists of two identical catalytic subunits to which two cone-specific inhibitory γ-
subunits (gene name: PDE6H) bind, rod PDE6 is a catalytic heterodimer (gene names: PDE6A and 
PDE6B) whose activity is regulated by two rod-specific inhibitory γ-subunits (gene name: PDE6G).   
In mammals, there are eleven Class I PDE families that share a highly conserved catalytic domain 
whose catalytic activity is regulated by the N-terminal regulatory domain {Conti, 2007 #6660;Francis, 
2011 #6969}. Of the eleven PDE families, five (PDE2, PDE5, PDE6, PDE10, and PDE11) contain two 
tandem regulatory GAF domains (GAFa and GAFb), so named for the identification of this protein 
domain in cGMP-binding phosphodiesterases, cyanobacterial Adenylyl cyclases and transcription factor 
FhlA {Heikaus, 2009 #6958}. Binding of cGMP to the GAFa domain of PDE5 results in allosteric 
stimulation of catalytic activity {Zoraghi, 2004 #5442;Wang, 2010 #6963;Biswas, 2011 #7075}. PDE6 
GAF domains are believed to serve multiple functions: (a) enhance dimerization of the catalytic subunits; 
(b) contribute to the high overall binding affinity of Pγ; and (c) communicate allosterically between the 
GAF and catalytic domains {Cote, 2006 #5841}.  
There is substantial biochemical evidence for allosteric regulation of rod PDE6 by its GAF 
domains. For example, binding of cGMP to the GAFa domain enhances the binding of Pγ to the rod 
PDE6 catalytic heterodimer, whereas binding of Pγ increases the affinity of cGMP to the noncatalytic 
cGMP binding site in GAFa {Muradov,  #4864;Zhang, 2008 #6869}. In addition, binding of PDE5/6 
inhibitor compounds to the enzyme active site decreases the rate of dissociation of cGMP from the GAFa 
domain {Zhang, 2008 #6869}. However, the structural and functional basis for this reciprocal allosteric 
regulation of PDE6 by binding of cGMP and Pγ is poorly understood. 
The x-ray crystal structures of several GAF-containing PDEs have been reported, including 
nearly full-length unliganded PDE2 {Pandit, 2009 #6985}, cGMP bound GAFab of PDE2 {Martinez, 
2002 #7575}, the unliganded GAFab dimer of PDE5 {Wang, 2010 #6963}, and the isolated GAFa 
domain of cone PDE6C with bound cGMP {Martinez, 2008 #6847}. More recently, a cryo-EM structure 
of rod PDE6 with cGMP  bound to the GAFa domains has been determined that provides hypotheses 
about the allosteric communication that may occur between the regulatory and catalytic domains {Gulati, 
2019 #7980}. However, experimental evidence is lacking on the structural changes that are induced by 
binding of cGMP or Pγ to the regulatory GAF domains. 
In this study, we report 3.3 Å x-ray crystal structure of the unliganded GAFab of PDE6C where 
its GAFa domain has close structural similarity to rod PDE6 and PDE5 GAFab domains but the PDE6C 
GAFb domain exhibiting significant structural differences. We hypothesized that binding of cGMP and 
Pγ induces discrete conformational changes that originate in the regulatory GAF domains and 
communicated to the catalytic domains, thereby providing a mode of allosteric regulation of the active 
lifetime of PDE6. To test this, chemical cross-linking and mass spectrometry analysis (CXMS) were used 
to characterize the conformational changes that occur upon binding of Pγ or/and cGMP to GAFab. 
Integrative structural modeling of the cross-linked peptides observed in the four possible liganded states 
(apo, cGMP bound, Pγ bound, and cGMP and Pγ bound) revealed discrete structural changes that occur in 
both GAFa and GAFb domains upon binding of cGMP or/and Pγ to GAFab. MD simulations of the cross-
link refined apo state structure and the cGMP-bound structure substantiated our hypothesis that cGMP 
binding induces conformational changes that are allosterically communicated to the GAFb domain, and 
also supported the idea that the homodimer has intrinsic structural asymmetry. NMR spectroscopy 
analysis of isotopically-labeled Pγ in the absence or presence of GAFab identified the central polycationic 
region of Pγ as the primary site of interaction with the GAFb domain of PDE6C. This study provides the 
most comprehensive analysis of allosterically-induced conformational changes in cone photoreceptor 
PDE6 that likely contributes to determining the basal activity and the activated lifetime of PDE6 during 
visual transduction in rod and cone photoreceptors. 
 
Results 
X-ray structure of the cone PDE6 regulatory GAF domains. 
Because of the inability to heterologously express full-length cone PDE6 catalytic subunits in sufficient 
quantities for structural studies {Gopalakrishna, 2016 #7647}, we relied on previous success with 
expression of PDE5 GAFab {Wang, 2010 #6963} and the isolated GAFa domain of chicken cone PDE6C 
{Martinez, 2008 #6847} to construct expression vectors for bacterial expression and purification of 
residues 42-458 of chicken cone PDE6C containing a 6His tag (Fig. S1A). We also expressed and 
purified the corresponding chicken cone Pγ subunit consisting of its first 58 residues. Purified 
recombinant GAFab was judged to be properly folded, based on its apparent MW observed by gel 
filtration as well as its ability to bind cGMP to the GAFa domain with a KD value (20 nM) similar to 
values reported previously [Fig. S1B; {Huang, 2004 #5662}].   
Purified PDE6C GAFab was then crystallized, and its structure determined from crystals in the 
space group of P65 with cell dimensions of a = b = 148.5, and c = 93.7 Å (Table 1). The structure was 
solved by using the PDE5 GAFab structure (Wang et al., 2010) as the initial model, and refined to R-
factor of 0.207 for 16489 reflections at 3.2 -50 Å resolution (Table 1). Residues 48-451 of the primary 
sequence of PDE6C were traceable, except for residues Lys286 to Thr309 (Fig. 2A, arrows). Fig. S2 
provides domain boundaries and secondary structure elements for the PDE6C GAFab structure. 
The PDE6 GAFab molecule is a homodimeric structure (Fig. 2A) that has the same fold as the 
homodimeric GAFab domains of PDE2 (Pandit, 2009) and  PDE5 (Wang et al., 2010), as well as with the 
heterodimeric rod PDE6 [Fig. 2B; (Irwin et al., 2019){Gulati, 2019 #7980}. The two subunits of the cone 
GAFab dimer overall exhibit  symmetry (RMSF = 0.74 Å; Fig. S1C). 
The structural superposition of the PDE6C GAFa (residues 74-225) over its cGMP complex from 
(Martinez et al., 2008) revealed an average shift of 0.6 Å for the Cα atoms, suggesting that cGMP binding 
does not induce dramatic conformational changes within the GAFa domain (Fig. 2C). The largest 
movement among the cGMP binding residues (Phe99, Leu115, Asn116, Phe136, Ser165, and Thr172, 
Figs. 2C and 2D) is 1.1 Å for the Cα Asn116 whose side chain forms a hydrogen bond with the base 
nitrogen of cGMP. 
A comparison of the rod {Irwin, 2019 #8185} and cone GAFab structures (Fig. 2A) reveals 
greater differences in the GAFb domains compared with more limited structural differences predicted for 
the GAFa domains (Fig. S3). Excluding the N-terminal and C-terminal regions, the average RMSD for 
GAFa was approximately 2-fold lower than for GAFb (mean RMSD values of 3.6  Å and 6.3 Å, 
respectively). These structural differences may reflect underlying functional differences in the allosteric 
regulatory mechanisms of rod and cone PDE6, especially in the GAFb domain where a previous study 
suggesting that the β1/β2 loop of GAFb may serve as a relay for signaling cGMP occupancy from the 
GAFa binding site to the active site in the catalytic domain {Gulati, 2019 #7980}. 
 
Solution structure of the unliganded state of GAFab determined by chemical cross-linking and 
mass spectrometry 
To investigate the allosteric regulation of the PDE6C GAFab regulatory domain, we first carried 
out chemical cross-linking coupled with liquid chromatography/mass spectrometry (XL-MS) to evaluate 
the structure of GAFab in solution and to create a structural model for the missing residues that were not 
resolved in the crystal structure. Fig. 3A shows a typical cross-linking experiment using BS3 that shows 
the appearance of gel-shifted bands corresponding to the cross-linked GAFab dimer. We also conducted 
cross-linking experiments in the presence of cGMP and/or Pγ1-58 (described below). The gel bands 
corresponding to the GAFab dimer (~100 kDa) were excised, proteolyzed, and analyzed by MS. Cross-
linked peptides identified for the GAFab apo state were used as spatial restraints for integrative structural 
modeling using the crystal structure as the template.  
Fig. 3B demonstrates that the solution structure of the apo state of GAFab, refined by spatial 
restraints imposed by more than 40 cross-links, was very similar to the x-ray structure in Fig. 2A. In 
particular, most of the α-helical and β-strand secondary structural features of the cross-linking-based 
structural model superimpose well with the crystal structure. Fig. S4 shows an RMSD plot as a function 
of amino acid residue number and includes the location of the cross-linking sites that were used in 
structural modeling of the GAFab solution structure in its apo state. Structural alignment of the GAFa 
domains of the apo and crystal structure (Fig. 3C) reveal that the spatial restraints imposed by the cross-
linking data result in significant differences in the solution structure in the α4 helix (near the opening to 
the cGMP binding site), and the β4 strand and adjoining loop region (residues 199 to 205). The GAFb 
domain of the solution structure also closely superimposes on the crystal structure (Fig. 3D), with the 
cross-linking results allowing us to generate a structural model for the β1/β2 loop (residues 288 to 310) 
that was missing in the crystal structure.  
 Structural differences of GAFab complexed with cGMP and/or Pγ revealed by chemical cross-
linking/MS analysis 
Fig. 4 compares the cross-link-refined structures for the apo GAFab with the cGMP-bound, Pγ-
bound, and cGMP and Pγ bound states. RMSD plots for the various liganded states (Fig. S5) show that 
binding of either cGMP or Pγ1-58 induces perturbations in the structures that are primarily localized to 
the GAFb β1/β2 loop region and the GAFa α4/β4 region. Both structural elements have been proposed to 
participate in allosteric communication from the GAF domains to the catalytic domains of PDE6 {Gulati, 
2019 #7980;Irwin, 2019 #8185}. 24 cross-links obtained from XL-MS analysis of the cGMP bound state 
of GAFab were used to refine apo structure to create a model for cGMP-bound GAFab. Comparison of 
cGMP bound versus the apo GAFab reveals a small conformational change in the α4 region of GAFa, 
consistent with previous studies.{Huang, 2004 #5662}. A conformational change in the GAFb β1/β2 loop 
that places it closer to the cGMP binding site in GAFa was supported by three cross-links (residues 169-
308, 308-289 and 288-305; Fig 4B). When comparing the cGMP-bound GAFa structure (PDBID: 3DBA) 
with our results, the α3,α4 and β strands forming the cGMP pocket in GAFa have similar conformations.  
We identified 54 cross-links that were used to model the structure of GAFab bound to Pγ, while 
59 cross-links were found for the cGMP/Pγ bound form of GAFab. In contrast to the apo GAFab or 
cGMP-bound states of GAFab, Pγ-bound GAFab  showed downward displacement of the GAFb β1/β2 
loop, similar to that reported for rod PDE6 {Gulati, 2019 #7980}{Irwin, 2019 #8185}. Binding of  Pγ to 
GAFab also resulted in displacement of GAFa domain particularly α4 region toward GAFb as compared 
to Apo GAFab (Fig 4A). Conformational changes observed in both Pγ and cGMP bound GAFab are 
similar to those found in only Pγ bound state of GAFab (Fig 4C).  
 
Molecular dynamics (MD) simulations of unliganded and cGMP-bound GAFab reveal subunit 
asymmetry and allosteric communication 
To evaluate the conformational dynamics and allosteric coupling within the two subunits of the 
PDE6 homodimer, we carried out three independent long time-scale MD simulations (see Methods and 
Table S1) of the PDE6 crystal structure as well as of the refined (based on cross-linking data) structural 
models of the PDE6 in the apo and cGMP-liganded states. For all simulations based on each of these 
PDE6 structures, we computed various conformational metrics (root mean squared deviation/fluctuation, 
RMSD/F; buried surface area, BSA; inter-domain center-of-mass distances, dynamic residue-residue 
cross correlation, DCC) that provide details on dynamics spanning individual residues to subdomains 
(GAFa/GAFb). The RMSD analysis reports on the flexibility of individual subdomains, RMSF reports on 
the flexibility of each amino acid residue, DCC analysis reports on correlated motions, while inter-domain 
center-of-mass distances and BSA report on the relative movements and buried surface areas between 
subdomains. 
Analysis of the crystal structure—assessment of the stability of the subdomain structural fold: In 
Fig. S6, we report data on conformational metrics based on simulations of the crystal structure of PDE6 
homodimer. The results based on RMSF and RMSD data (panels B and C in Fig. S6) show that the GAFa 
and LH1 subdomains in each subunit (Fig. S6A) are least flexible, while GAFb subdomains show 
bimodal RMSD distributions highlighting two distinct conformational states. The overall RMSD values 
for all subdomains range between 0-6 Å except those of the LH2 subdomains which range between 0-10 
Å (with mean values ~5 Å). The higher flexibility of the LH2 domain is due to their location at the free 
termini of subunits. We also observed that the BSA between GAFa subdomains (~70-280 Å2) is 
significantly higher than the BSA between GAFb subdomains (~0-120 Å2). We observed the highest BSA 
between the LH1 motifs (~1100-14000 Å2) followed by BSA between the C-terminal (~500-1100 Å2)  
and N-terminal helices (~300-800 Å2), respectively. Collectively, these data indicate that the overall 
subdomain folds resolved in the crystal structure as well as interfacial contact areas between subdomains 
are stably maintained in solutions states explored by MD simulations. 
 
Analysis of the apo and cGMP-liganded states of PDE6—subunit asymmetry and allosteric 
communication. In Fig. 5, we report ∆RMSF values comparing each chain of the homodimer in the apo 
and cGMP-liganded states. A value of ∆RMSF = 0 (or a very small difference) for each residue will 
indicate that the homodimer is dynamically evolving in a symmetric way with no major differences 
between individual chains and their subdomains. However, we observed that both GAFa and GAFb 
domains from each chain show a finite and non-negligible difference in flexibility per residue with GAFb 
domains showing more pronounced differences. This highlights asymmetric conformational evolution of 
the PDE6 homodimer both in the apo state and in the cGMP bound state.  
In Figs. S7 and S8, we report conformational metrics for the apo and cGMP-liganded states. 
These data highlight that the distributions of RMSD for GAFa subdomains are unimodal in the apo state, 
but bimodal in the cGMP bound state indicating a lower population of a moderately more flexible state on 
binding of cGMP. This trend is further captured in BSA distributions where more buried surface between 
GAFa domains is observed in the cGMP bound state of the homodimer in comparison to the apo-state 
suggesting that the GAFa subdomains move closer to each other on cGMP binding. For GAFb 
subdomains, we do not observe any major differences as the distributions of RMSD in both apo and 
cGMP bound states are bimodal. Similarly, for other structural motifs, the RMSD distributions do not 
highlight any major differences in flexibility, but BSA distributions show that the BSA between the 
helical motifs at the N- and C-terminus significantly increased on cGMP binding. This observation 
highlights allosteric perturbations on cGMP binding, mostly stabilizing interfaces between the terminal 
motifs. We surmise that the C-terminal helices moving closer could alter the conformation of catalytic 
domains thereby highlighting the role of cGMP in initiating allosteric communication. Our residue-
residue DCC analysis (Fig. 6) further showed signatures of asymmetry and allostery within the individual 
subunits of the PDE6 homodimer. For example, the LH2 motif showed increased correlation with 
residues in the GAFb subdomain of chain B on cGMP binding, while the same motif showed increased 
correlation with the GAFa subdomain in chain A on cGMP binding. We also observed that on cGMP 
binding, the LH1 motifs became more correlated with the GAFa subdomains in respective chains of the 
homodimer, while simultaneously several loops in GAFa/GAFb subdomains became less correlated 
within the respective chains. Collectively, MD simulation analyses provided evidence for the stability of 
the solution state fold of the PDE6 conformation observed in the crystal structure, or asymmetry in the 
dynamics of each chain, and allosteric perturbations on cGMP binding. 
 
Binding of the central region of Pγ to the GAFb domain  
Our XL-MS analysis identified 18 inter-subunit cross-links for the Pγ bound state of GAFab and 
17 inter-subunit cross-links for GAFab bound to both Pγ and cGMP. These cross-links permitted 
integrative structural modeling with the Integrated Modeling Platform to “dock” residues 23 to 50 of Pγ 
[using bovine rod Pγ as template {Irwin, 2019 #8185}]. Due to the fact that cone PDE6C is a homodimer, 
it was not possible to assign inter-molecular cross-linked peptides of Pγ and GAFab to one of the two 
subunits. For this reason, we applied all of the observed Pγ-GAFab cross-links to both subunits.  Residues 
23-50 of Pγ were identified as interacting with the GAFb domains, consistent with the localization of the 
homologous region of rod Pγ with the rod GAFb domains {Irwin, 2019 #8185}. Pγ docked similarly in 
both conditions Pγ_GAFab and Pγ_cGMP bound GAFab, and Fig7 shows the Pγ 23-50 docked in 
Pγ_GAFab  state. The absence of reactive lysine residues in the first 23 amino acids of the cone Pγ 
sequence prevented us from obtaining cross-linking results for the N-terminal region of Pγ. 
 
Characterization of cone Pγ1-58 and its binding to GAFab by solution NMR spectroscopy. 
Solution NMR spectroscopy was utilized to further characterize Pγ and its interactions with GAFab. 
Isotopically enriched Pγ (13C, 15N) was expressed in E. coli, purified, and standard 2-dimensional (2D) 
and 3-dimensional (3D) solution NMR experiments were performed for Pγ backbone and side chain 
assignments. The narrow dispersion of backbone 1H chemical shifts between 7.5 and 0.9 ppm in the2D  
1H-15N HSQC spectrum is indicative of the intrinsically disordered nature of Pγ. In contrast, well-ordered 
protein spectra are typically characterized by a wider dispersion of backbone 1H resonances well beyond 
the 1.5 ppm range of intrinsically disordered proteins. Based on 3D HNCA, HNCACB, and HNCO 
spectra, 46 of the 58 Pγ resonances were assigned (Fig 8A). The only residues that could not be assigned 
were the 9 prolines and the first 3 amino acids of the sequence.  
To probe the binding interface of Pγ, we mixed the chicken cone Pγ fragment (isotopically 
enriched) with the regulatory GAFab domain (unlabeled, natural abundance). The addition of GAFab 
induced significant changes in the Pγ 1H-15N HSQC spectrum (Fig 8B). The Pγ residues that make contact 
with GAFab are expected to exhibit the greatest chemical shift perturbations and NMR signal broadening 
resulting in signal attenuation. The most significant effects were observed for the F28-S38 region, where 
the peaks were barely detectable, very close to the baseline. Smaller attenuation and shifts were observed 
for neighboring residues (e.g. T20, G24, K27, and K42), which suggests that although these residues may 
not be directly interacting with GAFab, they are in close proximity to the binding interface and are 
affected by indirect effects. The N-terminal residues (N4-D13) of Pγ were the least affected by the 
binding, as inferred not only from the lack of chemical shift perturbations but the consistent NMR signal 
intensity of the free and bound Pγ. 
 
Discussion 
This paper reports determination of the x-ray crystal structure for the chicken cone PDE6C GAFab 
regulatory domains. In addition, we employed a number of structural approaches to examine 
conformational changes in the GAFab structure upon binding of cGMP and/or Pγ, including XL-MS 
combined with integrative structural modeling, MD simulations (to probe cGMP-induced allostery), and 
NMR spectroscopy (to identify Pγ residues that interact with GAFab).  
The overall x-ray structure depicts prototypical GAFa and GAFb domains with parallel organization 
of the two subunits, consistent with other GAF-containing PDEs, and shows the greatest structural 
homology with the homomeric PDE5 GAFab structure {Wang, 2010 #6963}. All of the secondary 
structure elements in the cone PDE6C GAFa and GAFb domains are closely aligned with those found in 
the GAFa and GAFb domains of the rod PDE6 catalytic heterodimer {Gulati, 2019 #7980}{Irwin, 2019 
#8185}. Similar to rod PDE6, cone PDE6 shows a long GAFa β1/β2 loop extending toward the GAFb 
domain, a structural feature not found in PDE2 {Martinez, 2002 #7575}. The failure to resolve the GAFb 
β1/β2 loop region likely reflects the disordered, dynamic nature of this region, and supports the 
hypothesis that this element may serve as an intermediary in the allosteric communication network 
originating in the GAFa domain and ending in the catalytic domain. MD simulation results further 
support conformational changes within this loop region and altered dynamics of this loop on cGMP 
binding. 
XL-MS coupled with integrative structural modeling of cone PDE6C GAFab provided the ability to 
compare the dynamic solution structure of GAFab to its static crystal structure. Overall, the cross-linked 
refined apo GAFab structure agrees quite well with the crystal structure but MD simulations provided 
additional information about flexible regions that may assume different conformations in solution 
compared to the crystalline state leading to asymmetry in subunits of PDE6 homodimer. Specifically, 
cross-links identified within the GAFb domain permitted us to develop a structural model for the β1/β2 
loop that was not resolved in the x-ray structure. Interestingly, the conformation of the β1/β2 loop in the 
apo GAFab structural model differs from published crystal structures of other GAF-containing PDEs as 
well as differing from the cryo-EM structure of bovine rod PDE6 {Gulati, 2019 #7980}. The mobility of 
this structural element is reflected in the different predicted conformations of the GAFb β1/β2 loop upon 
binding of cGMP or Pγ (Fig. 4). It appears that in the two states in which Pγ is bound, the β1/β2 loop is 
oriented in an extended downward conformation (i.e., toward the catalytic domain, were it to be present). 
We hypothesize that the binding of Pγ to the GAFb domain imposes conformational constraints that may 
orient it to participate in the proposed allosteric communication network. 
Previous studies have shown that binding of cGMP to its noncatalytic binding sites in the GAFa 
domain is modulated by Pγ binding [reviewed in {Cote, 2006 #5841}]. Both GAFab liganded states that 
have bound cGMP exhibit conformational changes in the region of the GAFa α4 helix supporting two 
possible, non-exclusive functional roles: (a) stabilizing cGMP binding by occluding the opening to the 
binding site to reduce cGMP dissociation; (b) sensing cGMP occupancy and communicating to Pγ or to 
other structural elements in the allosteric network. Overall, it appears that allosteric communication 
resulting from the state of occupancy of cyclic nucleotides in noncatalytic sites of GAF domains of GAF-
containing PDEs {Martinez, 2002 #4978} may rely on a similar relay of conformationally flexible regions 
within the GAFab domains. However, in the case of PDE6, it is evident from our comparison of the four 
GAFab liganded states (Fig. 4) that Pγ plays a dominant role in conveying allosteric changes in the GAF 
domains to the active sites within the catalytic domains.  
The convergence of the NMR and the XL-MS results in locating the major region of Pγ interaction to 
the GAFb domain (Figs. 7 and 8) is consistent with a role of the GAFb domain as the central hub of 
allosteric communication, linking cGMP-induced conformational changes the GAFa domain to an as-yet 
undetermined allosteric communication pathway in the catalytic domain that may be responsible for 
regulating the catalytic activity of PDE6 at the active site, or perhaps inducing conformational changes in 
the catalytic domain that alter the affinity with which transducin or RGS9-1 binds. Future efforts will be 
directed at obtaining additional structural information about the dynamic intra- and inter-molecular 
communication network of the PDE6 holoenzyme so that the regulation of PDE6 activation lifetime by 
the photoreceptor G protein and the RGS9-1 inactivation complex can be integrated with the GAFab 
allosteric communication network described in this study. 
 
Materials and Methods 
Expression and purification of the tandem GAF domains of cone PDE6 
The nucleotide sequence corresponding to amino acid residues 42-458 of the chicken cone PDE6 
catalytic subunit (UniProtKB P52731) was cloned into the pET47b expression vector containing a C-
terminal 6-His fusion tag. The sequence-verified construct was transformed into E. coli Rosetta cells and 
grown at 37 °C in LB media to an OD600 of ~0.8. Then, 0.05 mM isopropyl-β-D-1-thiogalactopyranoside 
was added and the cells incubated at 18 ºC for 18 h. The cell pellet was resuspended in 20 mM Tris, 100 
mM NaCl, pH 8.0 and disrupted by sonication. The recombinant protein was purified from the cell extract 
using a 1 ml HisTrap HP column with the GAFab protein being eluted from the resin with a buffer 
consisting of 100 mM imidazole, 100 mM NaCl and 20 mM Tris (pH 7.5). The affinity-purified protein 
was buffer exchanged with 50 mM Tris, 100 mM NaCl, 1 mM β-mercaptoehtanol, 1 mM EDTA, pH 7.5)  
prior to Superdex 200 gel filtration chromatography. The apparent molecular weight and purity of GAFab 
was evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Protein concentrations were 
determined by the bicinchoninic acid protein assay {Smith, 1985 #1322} using bovine gamma globulin as 
standard. Measurements of cGMP binding to GAFab were performed as described previously.  
 
Construction and purification of C-terminal truncated chicken cone Pγ1-58 
DNA fragments coding for chicken cone Pγ1-58 was inserted into the NdeI and BamHI sites of 
the pET11a vector, followed by transformation into the E. coli BL21(DE3) strain. Culture was grown on 
2X-TY media at 37ºC until O.D reached 0.6 followed by induction with 0.3mM IPTG. Cells were grown 
at 30C for 4hr after induction. Following expression, the bacterial extract was purified by HiTrap SP FF 
column from GE. The Pγ mutants were further purified by C18 reverse-phase high pressure liquid 
chromatography following standard procedure {Artemyev, 1998 #3585}. The purity of these proteins was 
determined to be >95% as evaluated by SDS-PAGE. Protein concentrations were evaluated by BCA 
protein assay using bovine γ-globulin as a standard.  
 
X-ray structure determination 
Chicken PDE6C GAF (42-458) protein in concentration of 8 mg/ml was crystallized by the hanging drop 
method at 40C. The drop was prepared by mixing 2 µl PDE6C sample with 2 µl well buffer that contains 
0.1 M Na-HEPES pH 7.5, 21-27% PEG3350, 0.2 M ammonium sulfate, and 20% glycerol. The crystals 
normally show up in 10 d and grow to the maximum size in 4 weeks. The crystals have the space group of 
P65 with cell dimensions of a = b = 148.5, and c = 93.7. The diffraction data of the unliganded PDE6C was 
collected on the SERCAT beam line of APS and processed by HKL2000 (Otwinowski and Minor, 1997, 
Table 1). The structure determination was solved by the AutoBuild module of PHENIX (Adams 
et al., 2010), using the PDE5 GAF as the initial model (Wang et al., 2010). The raw model of 
PDE6C was rebuilt with program COOT (Emsley et al., 2010) and refined by program REFMAC 
(Winn et al., 2003, Table 1) to an R-factor of 0.207 for 16489 reflection in the resolution of 50 – 
3.2 Å. 
 
Chemical cross-linking, in-gel digestion, and MS analysis 
Chemical cross-linking reactions were carried out following the manufacturer’s protocols for 
each cross-linker. PDE6 GAFab was buffer-exchanged into HEPES buffer (20 mM HEPES, 100 mM 
NaCl, 5 mM MgCl2, pH 8.0) and incubated with Pγ or/and cGMP. After incubating with cross-linker at 
RT for 1 h, proteins were separated with NuPAGE 4-12% Bis-Tris gels and visualized with Coomassie 
Brilliant Blue G-250.  
Bands representing cross-linked proteins were in-gel digested and analyzed by LC-MS and LC-
MS/MS as essentially described previously {Zeng-Elmore, 2014 #7444}. Briefly, the protein bands were 
excised from the SDS-PAGE gel and washed with 25 mM NH4HCO3/50% acetonitrile (ACN) to remove 
the Coomassie stain. Reduction of disulfide bonds were carried out by treating with 10mM DTT and later 
on cysteine alkylation was done with 55 mM iodoacetamide prepared in 25 mM NH4HCO3. Samples were 
dries out in speed vaccum. Dried gel pieces were treated with trypsin and asp-N (Promega) to cleave 
proteins in to peptides. The digested peptides were extracted from the gel pieces using 50%ACN, 
20%formic acid and 100%ACN solution in sequential manner and concentrated to ~7 µl using the 
Speedvac. One microliter aliquots of the  concentrated peptides were injected into the Dionex Ultimate 
3000 RSL Cnano UHPLC system (Dionex Corporation Sunnyvale, CA) and separated by a 75 µm × 25 
cm PepMAp RSLC column (100 Å, 2 µm) at a flow rate of ~450nl/min (mobile phase A:0.1% formic 
acid in H2O, mobile phase B:0.1% formic acid in 80% acetonitrile). The eluant was connected directly to 
a nano electrospray ionization source of an LTQ Orbitrap XL mass spectrometer (Thermo 
Scientific,Waltham,MA). LC-MS data were acquired in an information-dependent acquisition mode. Full 
MS spectra were acquired in the Orbitrap (m/z 315-2000) with a resolution of 30000 at m/z 400. The five 
most intense ions were selected for collision-induced dissociation (CID) fragmentation in the linear ion 
trap for MS/MS data acquisition. 
 
Cross-linked peptide identification  
Cross-linked peptides were identified using an integrated module in Protein Prospector, based on 
a bioinformatic strategy described previously {Chu, 2010 #7046;Trnka, 2014 #8096}. The score of a 
cross-linked peptide was based on the number and types of fragments ions identified, as wells as the 
sequence and the charge state of the cross-linked peptides. Only results where the score difference is 
greater than 0 (i.e the cross-linked peptide match was better than a single peptide match alone) are 
considered. The expectation values are calculated based on matches to single peptides and thus should be 
treated as another score, rather than a statistical measure of reliability. 
 
Structural modeling  
The GAFab x-ray crystal structure was used as template and cross-linking data was applied as 
distance restraints in Modeller v9.11 to obtain the cross-link refined solution structure of GAFab under all 
four condition as discussed above. Symmetry was enforced for the two subunits. The comparative model 
with lowest DOPE score (out of 10) was selected.  
To perform docking of Pγ to GAFab, the Integrated Modeling Platform [IMP; {Sali, 1993 
#7154}] was used with GAFab considered as a single rigid body, and Pγ residues 23-50 treated as a rigid 
body. The homologous Pγ residues from rod PDE6 holoenzyme {Irwin, 2019 #8185} were used as a 
template for initial docking, and IMP was run with a high temperature of 2.0, a low temperature of 0.5, 
and using a new system configuration at each step. The top 100 scoring models were generated and saved, 
and IMP was then used to perform clustering on the top 100 models in order to aid in model selection. 
The best fitting model was run in Modeller using the same cross-linking restraints in order to further 
refine the model, evaluate stereochemical quality, and fill in the missing atoms. Secondary structure 
identification was initially determined by Pymol version 2.3 (Schrodinger). 
 To evaluate potential differences between the two subunits of GAFab and to assess 
conformational changes occurring upon ligand binding, analysis of the root mean square deviations 
(RMSD) of our structural model with other available structures was carried out using Visual Molecular 
Dynamics (VMD) software version 1.9.3 {Humphrey, 1996 #8076}. 
 
System setup and MD simulation details 
The software Visual Molecular Dynamics (VMD) {Humphrey, 1996 #8076} was used to prepare 
all systems and analyze simulation  trajectories. All simulations were performed using the NAMD software 
{Phillips, 2005 #7709} with three different structures of GAFab: The x-ray structure  and the structural 
models (consisting of residues 42-458) of the unliganded (apo) and cGMP-bound GAFab states. We note 
that the x-ray structure PDE6 does not contain a portion of the GAFb β1/β2 flexible loop (residues 286-
310), whereas the two cross-link refined structural models include this loop. In the cGMP-bound structural 
model, a cGMP molecule was docked in each GAFa binding site based on the atomic coordinates of cGMP 
reported for the published chicken cone GAF structure (PDB ID: 3DBA).  
The three structures were solvated with TIP3P water molecules and the systems were neutralized 
with NaCl and MgCl2. After 500 steps of conjugate-gradient minimization, we equilibrated the volume of 
the simulation domain for each system by conducting a short 1 ns MD simulation in the NPT ensemble, 
after which we conducted three independent long time-scale MD simulations of each system (Table S1). In 
all simulations, we used a time-step of 2 fs and the CHARMM force-field for all molecules {MacKerell, 
1998 #7714;Mackerell, 2004 #7715;Huang, 2017 #8094}. The temperature was maintained (at 310 K) 
using a Langevin thermostat and the pressure (at 1 atm) using a Nosé-Hoover barostat. 
 
MD conformational metrics  
Root Mean Squared Deviation/Fluctuation (RMSD/RMSF): To understand the domain-level 
flexibility of PDE6 in various states (crystal structure, apo, and cGMP-bound states), we computed the 
RMSD as a metric based on the Cα atoms, where RMSD was measured relative to the initial structure in 
each simulation. A higher RMSD relative to the initial structure would indicate increased flexibility and 
vice-versa. The probability distributions of RMSDs of various domains of PDE6 are shown in Figs. S6-S8. 
To quantify the conformational flexibility of each residue, we further computed RMSF per residue for each 
subunit of PDE6. The RMSF calculations were based on all atoms in each residue. The RMSF data are 
shown in Figs. S6-S8. 
Buried surface area (BSA): To characterize interfacial area  between a pair of domains within 
PDE6, we calculated BSA between domains using the following equation: BSA = SASAa + SASAa′ −SASAaa′ 
where SASAa , SASAa′, and SASAaa′ are the solvent-accessible surface areas (SASA) of each domain 
individually  or both domains taken together. We used a probe radius of 1.4 Å for SASA calculations.  
Interdomain distances: To quantify the relative movement of individual domainsof PDE6, we 
measured distances between the center-of-mass (COM) of the following six pairs of domains in the 
homodimer: GAFa-GAFa’; GAFb-GAFb’; GAFa-GAFb; GAFa’-GAFb’; GAFa-GAFb’; and GAFa’-
GAFb. 
Dynamic Cross Correlation (DCC) Analysis: We also carried out residue-residue (Cα-Cα) DCC 
analysis for different states of PDE6. Specifically, for a pair of atoms i and j, the correlation coefficient 
Cij was computed using time-averaged displacements (∆ri and ∆rj) from the mean positions. 
 
NMR spectroscopy  
Uniformly 13C, 15N enriched Pγ was produced by expressing the protein in M9 minimal medium 
supplemented with 15NH4Cl and 13C6-glucose (for uniform labeling with nitrogen-15 and carbon-13), 
respectively. After purification, Pγ was resuspended in a buffer containing 20 mM Tris, 50 mM NaCl, 1 
mM MgCl2, pH 7.5. D2O, NaN3, and DSS were added for a final concentration of 5% v/v, 1 mM, and 200 
μM, respectively. NMR spectra were collected at 25 °C on a Bruker Avance III HD 700 MHz NMR 
spectrometer equipped with a quadruple resonance inverse QCI-F CryoProbe at the City University of 
New York Advanced Science Research Center (CUNY ASRC) Biomolecular NMR Facility and on a 
Bruker Avance NEO 700 MHz NMR spectrometer equipped with a 5-mm triple resonance inverse TCI 
CryoProbe at the University of New Hampshire Instrumentation Center NMR facility. For backbone and 
sidechain assignments, 2D 1H-15N HSQC, and 3D HNCA, HNCACB, and HNCO spectra were collected 
of 50 μM uniformly 13C,15N enriched Pγ. To investigate the binding properties of Pγ and GAFab, 
uniformly 13C,15N enriched Pγ (20 μM) and natural abundance GAFab (72 μM) were mixed, and 2D 1H-
15N HSQC spectra of Pγ were acquired (with and without GAFab). All NMR data were processed using 
NMRPipe {Delaglio, 1995 #8193}. Analysis and assignments of the 2D and 3D data sets were carried out 
using NMRFAM-Sparky {Lee, 2015 #8194}. The assignment process was facilitated by using the PINE 
server for initial automated assignments {Bahrami, 2009 #8192}{Lee, 2009 #8195} before completing 
the assignments manually. 
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Table 1.  Statistics on diffraction data and structure refinement of Unliganded PDE6C 
Data collection 
Space group P65 
Unit cell (a = b. c, Å) 148.5, 148.5, 93.7 
Resolution (Å) 3.2 
Wave length (Å) 1.0 
Unique reflections 16,737 
redundancy 4.8 fold 
Completeness (%) 86.0 (87.7)* 
Average I/σ 6.2 (1.9)* 
Rmerge 0.142 (0.712)* 
Refinement 
R-factor 0.207 
R-free 0.308 (5.0%)‡ 
Resolution (Å)  50-3.2 
     Bond (Å) 0.011 
     Angle 1.65o 
     Protein 72.5 (6251)§ 
Ramachandran Plot 
     Most favored 94.0 
     Allowed 5.8 
Generally allowed 0.2 
*The numbers in parentheses are for the highest resolution shell. 
‡The percentage of reflections omitted for calculation of R-free. 













Fig. 1. Multiple equilibria of ligand binding to PDE6 regulatory GAFab domains. The two 
tandem GAF domains (GAFa and GAFb) are denoted with blue circles, and the long helical 
regions and N- and C-termini collectively denoted as an elongated ellipsoid. cGMP binding to 






















Fig 2. Structure of cone PDE6 regulatory domains. A. X-ray structure of chicken cone PDE6 
GAFab at 3.3 Å resolution. Arrows indicate location of unresolved loop structure in the GAFb 
domain. B. Comparison of x-ray structure of cone PDE6 GAFab (green) with rod PDE6 catalytic 
dimer [dark blue; {Irwin, 2019 #8185}]. (C). Structural alignment of cone GAFa (green) x-ray 
structure with bovine rod PDE6 β-subunit GAFa domain (cyan; Irwin et al., 2019). (D) Changes 
of the cGMP binding residues. Cyan sticks represent the residues in the crystal structure of 
PDE6C-cGMP, while the corresponding residues of the unliganded PDE6C are shown as green 




Fig 3. Solution structure of the apo state of cone PDE6 GAFab determined by cross-
linking mass spectrometry.  A. SDS-PAGE of a cross-linking experiment in which 12 
µM GAFab was incubated in the presence or absence of cGMP(10 fold molar excess) 
and/or 120 µM Pγ1-58 prior to addition of a 50-fold molar excess of the chemical cross-
linker BS3. B. Structural alignment of cross-linked refined apo-GAFab (cyan) with x-ray 
structure (green). C. Superimposition of the GAFa domain of x-ray structure (green) and 
the apo structural model (cyan), with major differences indicated for the x-ray (red) and 
apo (blue). D. Superimposition of the GAFb domain of the x-ray structure (green) and the 
apo structure (cyan), with the β1/β2 loop (residues 285 to 310) of the apo structure 
highlighted in magenta that is missing in the x-ray structure. 
Fig 4. Structural models for PDE6 GAFab in various liganded states. A. Superimposition of 
GAFab in its apo (cyan) and Pγ-bound (yellow) states; significant structural differences are 
highlighted with red (apo) or magenta (Pγ bound). B. Comparison of apo GAFab (cyan) with 
cGMP-bound GAFab (magenta); differences are highlighted with red (apo) or yellow (cGMP 
bound). C. Superimposition of GAFab in its apo state (cyan) or with both Pγ and cGMP bound 
(blue); significant differences highlighted with red (apo) or purple (cGMP and Pγ bound). D. 
Comparison of the cGMP bound state of GAFab with (blue) or without (magenta) bound Pγ1-58; 






















Fig. 5. Molecular dynamics (MD) simulations of the apo and cGMP-liganded states of 
GAFab.  Differences in the root mean squared fluctuations (ΔRMSF) per residue were analyzed 
separately for each sub-domain of GAFab [N-terminal region of GAFa (N-GAFa, residues 55-
74), GAFa (residues 75-224), long helix-1 (LH1, residues 225-255), GAFb (residues 256-443), 
and long helix-2 (LH2, residues 434-453) to identify differences in protein dynamics of the apo 
and cGMP-bound states for each subunit. Any regions that differed more than 0.5 Å are 
highlighted in black on the accompanying structure.   A and B. Evaluation of asymmetry in 
protein dynamics of the two GAFab subunits in the apo (panel A) and cGMP-bound (panel B) 
state. C and D. Changes in protein dynamics upon cGMP binding to each subunit of GAFab 
were evaluated by plotting the ΔRMSF per residue for the apo and cGMP-liganded states for 
subunit A (panel C) and subunit B (panel D). 
 
 Fig. 6. Dynamic cross-correlation (DCC) analysis of the apo and cGMP-liganded states of 
GAFab.  (top) DCC maps corresponding to chain A and (bottom) DCC maps corresponding to 
chain B. The maps in the right-most panels are the difference between the cGMP-liganded states 
and the apo-states. Color bars indicated the range of correlations between 0 (no correlation) and 





















Fig. 7.  Integrative structural model of a fragment of cone Pγ complexed with PDE6 
GAFab. The Integrative Modelling Platform was used to dock cone Pγ (residues 23 to 50; shown 
as thick red lines) to GAFab, using the structural model for the corresponding region of bovine 
rod Pγ as template {Irwin, 2019 #8185}, and applying spatial restraints obtained from data for 
cross-linked peptides obtained in this region of the Pγ sequence. A. Pγ23-50 interacts with the 
GAFb domain of chain A. B. 180º rotation of Figure A showing the second Pγ23-50 fragment 





Fig. 8. Pγ1-58 NMR resonance assignments and binding studies. (A) 2D 1H-15N HSQC NMR 
spectrum of Pγ in its unbound state. Narrow dispersion of 1H chemical shifts between 9.0 and 7.5 
ppm is indicative of an intrinsically disordered protein. (B) The overlay of the 2D 1H-15N HSQC 
NMR specta of the unbound Pγ (red spectrum) and Pγ bound to GAFab (black spectrum) illustrates 
that the addition of GAFab induced significant changes in the Pγ spectrum. The most significant 
line broadening was observed in the F28-S38 region of Pγ, indicative of the binding interface.  
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Table S1. Cross-links identified for the apo state of PDE6C GAFab.  
 
 
Crosslinking conditions were followed as described in Fig. 3. Cross-linked peptides were 
identified following chemical cross-linking of apo GAFab and analyzed as described in Methods. 
Exp. m/z is the experimentally measured mass-to-charge ratio, z is the charge state of the 
peptide, and Δ is the accuracy measured in parts per million. The crosslinked peptides are 
defined by amino acid residue number (aa1, aa2) identified using the indicated crosslinker. 
m/z z ppm aa1 aa2 crosslinker
901.8438 3 3.3 395 396 Sulfo-SDA
1045.559 4 3.2 130 132 Sulfo-SDA
644.8098 4 14 263 450 Sulfo-SDA
516.0494 5 14 263 451 Sulfo-SDA
516.0497 5 14 263 452 Sulfo-SDA
514.6675 5 -0.061 160 163 Sulfo-SDA
1024.541 4 -15 130 214 Sulfo-SDA
1018.069 4 3.7 395 396 BS3
710.1106 4 6.1 288 305 BS3
947.9791 4 1.7 283 288 EDC
868.4985 3 9.8 395 398 EDC
516.0494 5 1.3 446 449 EDC
979.0488 4 3.8 395 397 EDC
650.0952 4 3 157 160 EDC
738.3666 4 2.6 289 305 EDC
815.715 7 5.9 150 179 EDC
562.5233 4 -0.091 160 368 Sulfo-SDA
567.1266 5 0.4 396 398 Sulfo-SDA
516.7652 4 -0.26 160 210 Sulfo-SDA
530.797 4 1.1 328 329 Sulfo-SDA
601.3285 4 -0.72 263 446 Sulfo-SDA
591.1158 5 -0.51 329 409 Sulfo-SDA
439.732 4 -0.2 263 439 Sulfo-SDA
708.6566 4 0.6 395 397 Sulfo-SDA
570.2784 4 1.4 234 412 Sulfo-SDA
524.5365 4 1 263 252 Sulfo-SDA
575.045 4 0.83 263 416 Sulfo-SDA
630.6795 3 0.33 263 264 Sulfo-SDA
545.5443 4 0.33 258 319 Sulfo-SDA
486.2567 4 -0.71 78 80 Sulfo-SDA
607.0844 4 1.3 133 150 Sulfo-SDA
539.7915 4 -0.81 95 160 Sulfo-SDA
609.0884 4 2.9 109 150 Sulfo-SDA
486.2571 4 0.12 77 82 Sulfo-SDA
524.5365 4 1 252 263 Sulfo-SDA
568.657 3 -0.74 395 439 Sulfo-SDA
486.2567 4 -0.71 78 80 Sulfo-SDA
522.4997 4 -0.9 288 293 Sulfo-SDA
570.2784 4 1.4 234 412 Sulfo-SDA
545.5443 4 0.33 258 319 Sulfo-SDA
630.6795 3 0.33 263 264 Sulfo-SDA
 
Table S2. Cross-links identified for the cGMP-liganded state of PDE6C GAFab. 
  
Crosslinking conditions were followed as described in Fig. 3 Cross-linked peptides were 
identified following chemical cross-linking of GAFab pre-incubated with cGMP and analyzed as 
described in Methods. Abbreviations are defined in the legend to Table S1. 
m/z z ppm aa1 aa2 crosslinker
901.8419 3 1.2 395 396 Sulfo-SDA
907.1179 3 2.5 286 288 Sulfo-SDA
1075.893 3 5.1 132 133 Sulfo-SDA
644.8436 2 1.2 305 306 Sulfo-SDA
644.8104 4 15 263 450 Sulfo-SDA
516.0493 5 14 263 452 Sulfo-SDA
516.0497 5 14 263 451 Sulfo-SDA
605.6481 3 0.79 308 311 Sulfo-SDA
688.8895 2 2.3 263 264 Sulfo-SDA
1045.561 4 5.4 132 138 Sulfo-SDA
680.8263 4 -14 169 308 Sulfo-SDA
488.7177 4 -4.1 151 170 Sulfo-SDA
710.1086 4 3.3 288 305 BS3
728.1359 4 4.6 159 180 BS3
947.9793 4 1.9 283 288 EDC
516.0505 5 3.4 446 449 EDC
911.1931 3 5.2 395 398 EDC
650.0953 4 3.2 157 160 EDC
738.368 4 4.5 289 308 EDC
430.8685 3 -1.1 286 287 Sulfo-SDA
486.2574 4 0.73 78 80 Sulfo-SDA
473.2619 4 1.5 263 264 Sulfo-SDA
473.2616 4 0.82 259 263 Sulfo-SDA
492.5123 4 2.1 258 319 Sulfo-SDA
Table S3. Cross-links identified for the Pγ-liganded state of PDE6C GAFab.  
 
Crosslinking conditions were followed as described in Fig. 3. Cross-linked peptides were 
identified following chemical cross-linking of GAFab pre-incubated with Pγ and analyzed as 
described in Methods. Abbreviations are defined in the legend to Table S1. 
 
 
m/z z ppm pep1 aa1 pep2 aa2 crosslinker
901.8422 3 1.5 GAFab 395 GAFab 396 Sulfo-SDA
1045.558 4 1.7 GAFab 130 GAFab 132 Sulfo-SDA
870.1294 3 -1.3 GAFab 263 GAFab 264 Sulfo-SDA
516.0483 5 12 GAFab 263 GAFab 452 Sulfo-SDA
708.6545 4 -2.4 GAFab 396 GAFab 408 Sulfo-SDA
605.6467 3 -1.5 GAFab 308 GAFab 311 Sulfo-SDA
868.4924 3 2.7 GAFab 395 GAFab 397 EDC
868.4937 3 4.2 GAFab 395 GAFab 398 EDC
866.4572 3 2.3 GAFab 157 GAFab 160 EDC
758.5859 5 3.3 GAFab 286 GAFab 289 EDC
947.98 4 2.7 GAFab 283 GAFab 288 EDC
516.0495 5 1.5 GAFab 446 GAFab 449 EDC
722.6653 4 3.5 GAFab 395 GAFab 396 BS3
1024.528 3 0.0031 GAFab 132 GAFab 171 BS3
517.0277 4 -0.45 GAFab 263 GAFab 441 BS3
687.1057 4 -0.2 GAFab 78 GAFab 122 BS3
464.6031 3 1 GAFab 151 GAFab 169 BS3
504.0407 4 -0.15 GAFab 396 GAFab 441 BS3
611.3097 3 -4.3 GAFab 132 GAFab 160 BS3
599.6564 3 4.3 GAFab 151 GAFab 214 BS3
605.3181 3 -0.39 GAFab 319 GAFab 441 BS3
646.8674 2 2 GAFab 151 GAFab 170 BS3
427.9638 4 -1.3 GAFab 441 GAFab 444 BS3
751.768 3 1.8 GAFab 385 GAFab 386 Sulfo-SDA
1047.882 3 2.3 GAFab 188 GAFab 189 Sulfo-SDA
786.1621 4 0.69 GAFab 188 GAFab 190 Sulfo-SDA
901.8417 3 0.95 GAFab 396 GAFab 397 Sulfo-SDA
708.6566 4 0.58 GAFab 396 GAFab 400 Sulfo-SDA
727.0612 3 0.53 GAFab 199 GAFab 200 Sulfo-SDA
902.1306 3 1.8 GAFab 156 GAFab 171 Sulfo-SDA
730.3585 2 0.0019 GAFab 78 GAFab 79 Sulfo-SDA
674.8718 2 0.34 GAFab 122 GAFab 123 Sulfo-SDA
715.8451 2 -0.63 GAFab 374 GAFab 375 Sulfo-SDA
632.3214 2 -0.51 GAFab 444 GAFab 445 Sulfo-SDA
482.2609 3 -0.052 GAFab 328 GAFab 329 Sulfo-SDA
707.3934 3 0.88 GAFab 328 GAFab 330 Sulfo-SDA
707.3923 3 -0.68 GAFab 328 GAFab 333 Sulfo-SDA
850.9415 2 0.93 GAFab 130 GAFab 132 Sulfo-SDA
644.8423 2 -0.79 GAFab 305 GAFab 306 Sulfo-SDA
988.9966 2 0.39 GAFab 132 GAFab 134 Sulfo-SDA
988.9964 2 0.19 GAFab 132 GAFab 135 Sulfo-SDA
760.0797 3 1.3 GAFab 122 GAFab 135 Sulfo-SDA
819.9417 2 1.4 GAFab 256 GAFab 319 Sulfo-SDA
568.6575 3 0.078 GAFab 395 GAFab 439 Sulfo-SDA
681.7285 3 -1.3 GAFab 255 GAFab 395 Sulfo-SDA
632.3215 2 -0.35 GAFab 441 GAFab 446 Sulfo-SDA
547.838 2 0.61 GAFab 82 GAFab 83 Sulfo-SDA
1006.506 2 0.51 GAFab 249 GAFab 250 Sulfo-SDA
743.8929 2 -0.18 GAFab 305 GAFab 308 Sulfo-SDA
707.3939 3 1.6 GAFab 327 GAFab 332 Sulfo-SDA
738.4125 3 0.59 GAFab 211 GAFab 215 Sulfo-SDA
699.0277 3 -1.6 GAFab 150 GAFab 170 Sulfo-SDA
752.1006 3 -8.2 GAFab 132 GAFab 386 Sulfo-SDA
593.572 4 0.23 GAFab 151 GAFab 209 Sulfo-SDA
430.2307 3 -0.62 GAFab 304 GAFab 308 Sulfo-SDA
Table S4. Cross-links identified for the Pγ- and cGMP-liganded state of PDE6C GAFab.  
 
Crosslinking conditions were followed as described in Fig. 3. Cross-linked peptides were 
identified following chemical cross-linking of GAFab pre-incubated with Pγ and cGMP and 
analyzed as described in Methods. Abbreviations are defined in the legend to Table S1. 
  
m/z z ppm pep1 aa1 pep2 aa2 crosslinker
579.2989 4 -0.43 GAFab 396 GAFab 441 BS3
1024.528 3 0.3 GAFab 132 GAFab 171 BS3
595.8455 4 0.13 GAFab 82 GAFab 122 BS3
413.8239 5 0.24 GAFab 263 GAFab 441 BS3
813.7858 3 -0.26 GAFab 263 GAFab 319 BS3
528.5142 5 -0.91 GAFab 263 GAFab 396 BS3
695.0345 3 -0.14 GAFab 319 GAFab 444 BS3
605.3187 3 0.61 GAFab 319 GAFab 441 BS3
464.6026 3 -0.048 GAFab 151 GAFab 159 BS3
687.1059 4 0.09 GAFab 78 GAFab 122 BS3
599.6541 3 0.46 GAFab 151 GAFab 214 BS3
751.7666 3 -0.022 GAFab 385 GAFab 386 Sulfo-SDA
901.8412 3 0.4 GAFab 385 GAFab 387 Sulfo-SDA
1047.881 3 0.9 GAFab 188 GAFab 189 Sulfo-SDA
821.0855 3 2.7 GAFab 168 GAFab 171 Sulfo-SDA
766.4034 3 -1.5 GAFab 103 GAFab 171 Sulfo-SDA
1018.539 3 0.68 GAFab 95 GAFab 171 Sulfo-SDA
708.6578 4 2.3 GAFab 396 GAFab 397 Sulfo-SDA
901.8425 3 1.8 GAFab 395 GAFab 396 Sulfo-SDA
676.6326 4 0.22 GAFab 393 GAFab 396 Sulfo-SDA
574.6073 3 0.94 GAFab 367 GAFab 412 Sulfo-SDA
730.3586 2 0.14 GAFab 78 GAFab 79 Sulfo-SDA
722.8879 2 0.21 GAFab 328 GAFab 329 Sulfo-SDA
361.9468 4 -2 GAFab 328 GAFab 330 Sulfo-SDA
973.8683 3 1.3 GAFab 132 GAFab 216 Sulfo-SDA
630.6799 3 1 GAFab 263 GAFab 264 Sulfo-SDA
1084.557 2 0.42 GAFab 249 GAFab 250 Sulfo-SDA
644.8433 2 0.76 GAFab 305 GAFab 306 Sulfo-SDA
787.054 3 -0.77 GAFab 374 GAFab 378 Sulfo-SDA
787.0552 3 0.76 GAFab 374 GAFab 379 Sulfo-SDA
1060.587 2 1.2 GAFab 328 GAFab 333 Sulfo-SDA
988.9967 2 0.49 GAFab 132 GAFab 134 Sulfo-SDA
681.7287 3 -1 GAFab 255 GAFab 395 Sulfo-SDA
1006.506 2 0.51 GAFab 249 GAFab 251 Sulfo-SDA
674.8718 2 0.34 GAFab 122 GAFab 123 Sulfo-SDA
977.5193 3 1.2 GAFab 122 GAFab 126 Sulfo-SDA
632.322 2 0.44 GAFab 441 GAFab 445 Sulfo-SDA
988.9957 2 -0.52 GAFab 132 GAFab 133 Sulfo-SDA
659.6673 3 1.1 GAFab 132 GAFab 135 Sulfo-SDA
988.9973 2 1.1 GAFab 130 GAFab 132 Sulfo-SDA
715.8455 2 -0.07 GAFab 374 GAFab 375 Sulfo-SDA
743.8934 2 0.5 GAFab 305 GAFab 308 Sulfo-SDA
653.7973 2 0.14 GAFab 286 GAFab 288 Sulfo-SDA
568.6575 3 0.078 GAFab 395 GAFab 439 Sulfo-SDA
681.7287 3 -1 GAFab 255 GAFab 395 Sulfo-SDA
648.6512 3 0.26 GAFab 257 GAFab 374 Sulfo-SDA
819.9401 2 -0.5 GAFab 258 GAFab 319 Sulfo-SDA
577.9899 3 1.4 GAFab 395 GAFab 415 Sulfo-SDA
707.3931 3 0.45 GAFab 327 GAFab 332 Sulfo-SDA
547.8376 2 -0.12 GAFab 82 GAFab 83 Sulfo-SDA
363.8491 3 0.37 GAFab 161 GAFab 170 Sulfo-SDA
514.6675 5 -0.061 GAFab 160 GAFab 163 Sulfo-SDA
868.4938 3 4.3 GAFab 395 GAFab 397 EDC
650.0968 4 5.5 GAFab 157 GAFab 160 EDC
793.4263 3 5.9 GAFab 311 GAFab 319 EDC
947.981 4 3.7 GAFab 283 GAFab 288 EDC
516.0496 5 1.7 GAFab 446 GAFab 449 EDC
713.8801 8 11 GAFab 150 GAFab 179 EDC
738.3687 4 5.4 GAFab 289 GAFab 305 EDC
Table S5. Inter-molecular cross-links identified for the Pγ-liganded state of PDE6C 
GAFab.  
 
Crosslinking conditions were followed as described in Fig. 3. Inter-molecular cross-linked 
peptides were identified following chemical cross-linking of GAFab pre-incubated with Pγ and 
analyzed as described in Methods. Abbreviations are defined in the legend to Table S1. 
  
m/z z ppm pep1 aa1 pep2 aa2 crosslinker
676.1063 4 -0.67 Pγ 29 GAFab 171 BS3
663.1042 4 -1.5 Pγ 23 GAFab 171 BS3
682.6824 3 -0.22 Pγ 29 GAFab 374 BS3
665.3475 3 0.5 Pγ 23 GAFab 374 BS3
449.0375 4 1.3 Pγ 43 GAFab 396 BS3
797.4662 2 0.042 Pγ 43 GAFab 319 BS3
378.975 4 -0.18 Pγ 43 GAFab 409 BS3
378.9749 4 -0.44 Pγ 42 GAFab 409 BS3
863.9749 2 0.63 Pγ 46 GAFab 319 BS3
573.6633 3 1.5 Pγ 39 GAFab 319 BS3
493.2857 4 -0.62 Pγ 39 GAFab 263 BS3
610.3389 2 -0.79 Pγ 43 GAFab 441 BS3
451.567 3 -1 Pγ 46 GAFab 441 BS3
655.366 3 -0.86 Pγ 29 GAFab 122 BS3
473.226 3 8.4 Pγ 27 GAFab 78 BS3
421.97 4 0.042 Pγ 23 GAFab 368 Sulfo-SDA
842.9329 2 0.25 Pγ 23 GAFab 369 Sulfo-SDA
475.7602 4 -2.1 Pγ 49 GAFab 263 Sulfo-SDA
Table S6. Parameters for MD simulations  
 
# Atoms Water Length Runs Box size  
X-ray 113990 33856 500 ns 3 87 Å × 131 Å × 107 Å 
apo state 104728 30533 360 ns 3 88 Å × 120 Å × 107 Å 
cGMP bound  104792 30531 360 ns 3 88 Å × 120 Å × 107 Å 
 
Details of MD simulations on three different systems are highlighted including the numbers of 
total and water atoms in each simulation, the length of each trajectory (3 independent simulations 




Fig S1. Purification, cGMP binding properties, and initial characterization of structural 
asymmetry of chain A and chain B of the x-ray structure. A. SDS-PAGE of purified, 
recombinant chicken cone PDE6 GAFab (PDE6C, residues 42-458) and chicken cone Pγ1-58. 
Lane 1, affinity-purified GAFab; Lane 2, gel filtration-purified GAFab; Lane 3, HPLC-purified 
Pγ1-58. B. Binding curve of 1.5 nM GAFab incubated with increasing concentrations of 
[3H]cGMP; the solid line represents fitting the data to a hyperbolic curve, with a KD = 20 nM. C. 
RMSD analysis of chain A versus chain B of the chicken cone PDE6 GAFab x-ray structure; 






































Fig. S2. Structural alignment of cone PDE6C regulatory domains. The chicken cone PDE6 
amino acid sequence (PDE6C_CHICK, P52731) was aligned with the two subunits of the crystal 
structure (Fig. 2A) with secondary structure elements highlighted in red (α-helix) or green (β-
strand). The boundaries for the GAFa (residues 75-224) and GAFb (residues 256-433) domains 
(black arrows) are defined according to their Pfam (PF01590) entry. 
  
  
Fig. S3. Structural comparison of the GAF domains of rod and cone PDE6. A. The GAFa 
domain (residues 55-224 of the chicken cone sequence and the corresponding residues (59-228) 
of the bovine rod β-subunit {Irwin, 2019 #7890}) were aligned, and the RMSD values for each 
residue were determined. The overall average RMSD = ?? Å, and omitting the LH1 and LH2 
regions resulted in an average RMSD = ?? Å. B. Comparative RMSD analysis of the GAFb 
domain of chicken cone (residues 225-453) with the bovine rod β-subunit (residues 229-457). 
The overall average RMSD = ?? Å, and omitting the LH1 and LH2 regions resulted in an 





































Fig. S4. RMSD analysis of the chicken cone GAFab x-ray structure versus the cross link-
refined apo GAFab structure. The black and red lines represent RMSD values for A and B 
subunits of GAFab, respectively. Black circles identify intra-molecular crosslinked residues of 



















Fig. S5. RMSD plots for various liganded states of GAFab. RMSD per residue was calculated 
after aligning the apo GAFab structure with other liganded states. A. apo state versus Pγ1-58 
bound to GAFab. B. apo state versus cGMP bound to GAFab. C. apo state versus Pγ1-58 plus 
cGMP bound to GAFab. D. RMSD per residue analysis between the Pγ-bound and Pγ- plus 
cGMP-bound GAFab. The black and red lines represent RMSD values for A and B subunits of 
GAFAB, respectively. Black circles represent intra-molecular crosslinked residues identified for 
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Fig. S6. Dynamics and stability of the crystal structure of the PDE6 GAFab homodimer as 
characterized by various conformational metrics. (A) Cartoon representation of the x-ray 
structure with color scheme for the subdomains characterized in panels B-D. (B) Root mean 
squared fluctutation (RMSF) per residue for each subunit, color-coded to correspond with the 
representation in panel A; (C) the probability distributions of the root mean squared deviation 
(RMSD) for individual domains of each subunit; (D) the distributions of the buried surface area 
(BSA) between various domains of the homodimer. Vertical lines marked on distributions 
correspond to mean values of the RMSD data from simulations (panel C) and the BSA values 
















Fig. S7. Conformational metrics highlighting dynamics of the apo state of the PDE6 GAFab 
















Fig. S8. Conformational metrics highlighting the dynamics of the cGMP-bound state of the 
PDE6 GAFab homodimer. For the cGMP-bound state of PDE6 (A), data similar to Fig. S6 are 
highlighted in panels B-D.  
 
